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Abstract
Background: Hemoptysis is a significant clinical presentation in respiratory medicine. Often a life
threatening emergency, it mandates prompt assessment and intervention. Various investigations
and management protocols are proposed globally, to advocate a standardized approach towards
patients presenting with hemoptysis. It is the etiology, however, that has been known to influence
clinical outcome and prognosis. With marked contrast in geographical patterns of pulmonary
pathologies, etiological agents for hemoptysis vary over the world. Studies in West, usually
demonstrate neoplastic and non-granulomatous causes to be the leading agents for hemoptysis.
The diagnostic accuracy of various investigations and efficacy of management alternatives has been
established there. Developing nations differ in their burden of diseases of lung. Lack of health
resources and initiative often prevent quality research in critical areas.
Design: This is a retrospective observational study with a cross-sectional design in which charts
of all patients admitted with the presentation of haemoptysis in the past ten years will be reviewed,
at Aga Khan University Hospital, Karachi, Pakistan. A series of variables, based on previous
literature on haemoptysis related to the objectives of present study, will be determined in the
study. Demographics, co-morbids and etiology will be determined. Findings of various investigation
modalities and their accuracy in localizing the bleeding site will be determined. Efficacy of different
management strategies will also be observed. Also observed will be any complications and follow-
up.
Discussion: Pakistan is a third world nation of over 150 million, established as highly endemic for
pulmonary tuberculosis. To date no study has been generated to look into hemoptysis patterns, in
this nation. Lack of evidence based medicine poses a major hindrance towards confident decision-
making in the approach towards a patient presenting with hemoptysis in this country. This study is
devised to obtain the first insight in this direction, from this part of the world. The etiologies,
accuracy of various investigations and efficacy of treatment options will be investigated. The results
and conclusions will prove to be of value not just for health administrators in this country, but many
other regions that share similarities in patterns of pulmonary pathologies.
Background
Hemoptysis refers to expectoration of blood from respira-
tory tract. Often lethal, it is a frightening presentation for
patient and relatives. A major emergency in pulmonary
medicine, it necessitates a timely and apt approach.
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While emergency resuscitation protocols may overlap,
medical advance is usually directed on basis of severity
and etiology of hemoptysis. Apposite clinical assessment
and investigations are thus paramount in formulating the
management proposal. After adequate airway protection
and insurance of ventilatory and cardiovascular stability,
in case of gross hemoptysis, imaging is usually resorted to,
for indication of the pathology and localization of bleed-
ing site. Chest roentgenography is frequently valuable in
illustrating the disease process [1]. Computed tomogra-
phy has also been established in recent decades as a par-
ticularly sensitive diagnostic and localizing tool in
hemoptysis [2]. Endoscopic assessment, however, by rigid
and/or flexible bronchoscopy is often warranted. Both a
diagnostic and therapeutic tool, it is aimed to lateralize
the bleeding side; localize the bleeding site and identify
the cause [3,4]. In case of rapid and severe hemorrhage
making airway visualization impossible, emergent rigid
bronchoscopy or arteriography may be employed, for suc-
cessful isolation and subsequent clogging of the bleeding
vessel.
Management approach is prioritized to control ongoing
hemoptysis with endotracheal intubation and intensive
care monitoring. In cases with lateralized or localized per-
sistent bleeding immediate, albeit transient, control of the
airway may be obtained with topical therapy, endobron-
chial tamponade, or unilateral intubation of the non-
bleeding lung. Angioembolization of the pathologic
bleeding bronchial arterial vessels is now globally recom-
mended as the treatment of choice in most cases [3,5].
Apart from being a definitive treatment modality, it pro-
vides valuable time and prevents bleeding during opera-
tion in patients undergoing subsequent surgical
intervention. Conservative management is generally pre-
ferred and associated with lesser mortality rates [6,7]. Sur-
gery is usually advocated in case of failure of
embolotherapy, persistent hemodynamic and respiratory
compromise and accurate identification of the bleeding
site. Lobectomy, pneumectomy, wedge resection, segmen-
tectomy or a combination of these approaches may be
adapted. Emergent resection, however, is associated with
greater risks in comparison to elective surgery [8], and
should generally be reserved for when general condition
and vital organs of the patient would permit surgical ther-
apy.
Even as principal focus in critical presentation is directed
towards identification and stoppage of the source of
bleeding, it is the primary etiology that dictates the clini-
cal course and treatment strategy [9,10]. Overall clinical
outcome is reflected by the generalized nature of the
destructive pathology and respiratory reserve. Etiology is
varied and includes bronchiectasis, lung cancer, active or
old tuberculosis, primary pulmonary fungal infection,
lung abscess, bronchitis, pneumonia, bronchovascular fis-
tula along with rheumatic heart disease, carcinoid and a
couple of other rare causes. Together with operatibilty and
rate of bleeding, these pathologies often determine the
outcome. Operable patients and those with lesser rates of
bleeding generally have a better prognosis [10]. Similar
can be said about non-malignant causes of hemoptysis
[2]. Massive hemoptysis, bleeding diathesis and lung neo-
plasms, however, have poorer outcomes.
Methods/design
Study design
It is an observational study with a cross-sectional design in
which charts of all patients admitted with the presenta-
tion of haemoptysis in the past ten years will be reviewed.
Setting
Aga Khan University Hospital, Karachi, Pakistan.
Data collection
All patients with hemoptysis (mild, moderate or massive)
will be included in this study. Prevalence is likely to vary
with age. It is expected to be markedly different for pedi-
atric age group. Only adult patients (eighteen years or
older) are included in this study.
A series of variables, based on previous literature on hae-
moptysis related to the objectives of present study, will be
determined in the study. Apart from demographics, these
include smoking status, co-morbids, medications, previ-
ous hemoptysis, and the quantity of bleeding during the
current episode to classify into mild, moderate or massive
hemoptysis. Certain clinical features at the time of presen-
tation like hypotension; tachycardia; tachypnea; hypoxia;
bronchial breathing; wheezing, and crackles on chest aus-
cultation, will be noted. Certain baseline investigations
including levels of hemoglobin; blood urea nitrogen; cre-
atinine and alanine transaminase, leucocytes and platelet
count plus prothrombin time and activated partial throm-
boplastin time, will also be taken note of. Also observed
will be the chest roentgenographic findings, as reported
by a consultant radiologist at the institution, including
presence of any infiltrates, cavity, consolidation, bron-
chiectasis, mass or any other significant element. Similar
features of computed tomographic scan will be observed.
Bronchoscopy findings included would be presence/
absence of active hemoptysis and identification of bleed-
ing site into the specific lobe.
Cause of hemoptysis would then be taken note of. In case
of infectious processes the determination of etiology will
be made through the microbiological analyses of culture
findings (e.g. sputum culture and/or smear, in cases where
culture evidence is unavailable, analysis for acid fast bac-
teria for identification of mycobacterium tuberculosis).
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For neoplastic processes, histopathological evidence will
be recorded for determination of the malignancy.
The treatment modality e.g. embolotherapy, surgery or
other would be marked. During of hospitalization and
any complications following the management approach
adapted, would be noted. Also included would be the out-
come, six monthly follow-up and in case of mortality dur-
ing the period, cause of death.
The above-mentioned queries would be incorporated into
an observational checklist that would serve as the data col-
lection tool.
The primary objective therefore of this study is to deter-
mine the role of various etiological agents in contributing
towards hemoptysis presentation. It is hypothesized that
infectious, rather than neoplastic, etiologies would con-
tribute mainly towards hemoptysis presentation in this
setting.
The other objectives include determination of the role of
various investigations, i.e. chest x-ray and CT scanning, in
correctly identifying the bleeding site; to determine the
demographics of patients presenting with hemoptysis;
and to compare the success rates of various management
alternatives mentioned in stopping the bleeding.
Results
Data analysis will be carried out by entering the data into
the Microsoft Windows based Statistical Package for the
Social Sciences (SPSS- released 10.1, standard version,
copyright SPSS; 1989–1999). Anonymity of the subjects
will be maintained. Diagnostic accuracy of various inves-
tigations will be calculated and outcome of different treat-
ment modalities like surgery and embolization will be
compared, the outcome of interest being stoppage of
bleeding. Multivariate analysis will be employed.
Positive and negative predictive value of each diagnostic
investigation will be calculated by assessing their ability to
correctly identify the site of bleeding. Chest x-ray and CT
scanning will be assessed in this manner. Also sensitivity
and specificity of each investigation will be assessed by
finding proportion of patients with condition who test
positive, and proportion of patients without condition
who test negative, respectively. For judging the ability of
each investigation to discriminate between diseased and
non-diseased persons, receiver operator curves may be
plotted.
Discussion
Over the world there is a marked geographical variation
between the causative agents of hemoptysis. Despite the
increase in HIV-associated tuberculosis in the west, stud-
ies there usually demonstrate malignancy and other non-
tuberculous causes as the leading agents [2]. Developing
world, largely endemic to tuberculosis, bears the brunt of
the disease. Trials have shown tuberculosis to be the
major source of hemoptysis in these nations [1,11]. Lack-
ing finances and sufficient health resources, they lack
indigenous studies and formal protocols on the approach
to hemoptysis, based on their locoregional causative fac-
tors.
This study, generated from a third world country where
tuberculosis is endemic [12], aims to obtain a thorough
picture of the patterns of hemoptysis in this nation. Apart
from demographics it will provide the various etiologic
agents and their proportionality in contributing towards
hemoptysis presentation in this country; different investi-
gation techniques and their success rates in positive iden-
tification of the disease process; various management
strategies and their results plus follow up and outcome
determination.
It is the first trial of this kind from this part of the world
and the results generated will contribute greatly to the
knowledge and policy making of health system in not just
the subcontinent, but also major parts of the world, which
share similarities in disease patterns of the lung.
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